Skip to content
Bored Studies
RecruitingAccepts healthy volunteers

Serologic Response to Pneumococcal Vaccination Among Esophageal Cancer Patients With High Grade Lymphopenia After Chemoradiation

M.D. Anderson Cancer Center · NCT06181656

View Study & Apply (opens in a new tab)

Opens the official ClinicalTrials.gov record, with the study team’s contacts. Bored Studies doesn’t enroll anyone.

Key facts

Compensation
Not posted. Ask the study team before screening.
Who can join
Ages 18+ · All sexes
Healthy volunteers
Accepted
Study type
Observational
Target enrollment
80
US sites recruiting
1
Study start
February 5, 2024
Record last updated
May 20, 2026

Status re-checked against ClinicalTrials.gov within the last 12 hours.

What the study is about

To learn how radiation treatment may affect your responses to vaccines against pneumonia.

Being studied: Pneumonia vaccine

Conditions: Pneumococcal Vaccine; Esophageal Cancer; Lymphopenia; Chemoradiation

Eligibility criteria

Copied from the official record. The study team makes the final decision at screening.

Show full criteria

Inclusion Criteria

  • Group 1A

a. Patients currently receiving, planning to receive, or recently completed chemoradiation for esophageal cancer with protons.

  • Group 1B

a. Patients currently receiving, planning to receive, or recently completed chemoradiation for esophageal cancer with intensity-modulated radiation therapy (IMRT)

  • Group 2A

a. Patients currently receiving, planning to receive, or recently completed definitive proton therapy for unresectable liver cancer.

  • Group 2B

a. Patients currently receiving, planning to receive, or recently completed definitive IMRT for unresectable liver cancer.

  • Group 3

a. Healthy age- and gender- matched individuals

  • All Groups
  • Patients of all genders, races and nationalities will be solicited.
  • Age >18 years
  • Ability to understand and the willingness to sign a written informed consent document.

Exclusion Criteria

  • Patients with compromised immunologic responses due to an uncontrolled intercurrent immunodeficiency (e.g., Human immunodeficiency virus (HIV), X-linked agammaglobulinemia) or previous or current immune suppressive therapy

a. Human immunodeficiency virus (HIV)-infected patients on effective anti-retroviral therapy with undetectable viral load within 6 months are eligible for this trial.

  • Patients receiving intravenous immunoglobulin (IVIG) during the study or in the three months prior to study enrollment.
  • Patients with psychiatric illness/social situations that would limit compliance with study requirements.
  • Individuals with previous pneumococcal vaccination in the last 5 years.
  • Individuals with severe allergy to any of the vaccine components

Recruiting US locations

  • MD Anderson Cancer Center

    Houston, TX 77030

    Site contact: Steven H Lin, MD · 713-563-8490 · shlin@mdanderson.org

Study contacts (from the official record)

  • Steven H Lin, MD · (713) 563-8490 · shlin@mdanderson.org
All vaccine studies in Texas →
Serologic Response to Pneumococcal Vaccination Among Esophageal… (NCT06181656) | Bored Studies